MabSpace Biosciences Co., Ltd, a biotechnology company focused on the discovery and early development of antibody based therapeutics, has signed a collaborative contract of a novel therapeutic antibody with Genor Biopharma Co. Ltd (GenorBio), the mAb division of Walvax Group, one of the leading therapeutic antibody development companies in China.
According to the agreement, MabSpace will be responsible for the discovery and selection of fully human lead antibodies and GenorBio for the further development of the selected candidate molecules.
GenorBio will own exclusive global rights on the resulting therapeutic candidates for the nominated targets, while MabSpace will receive upfront R&D funding, regulatory milestones and royalty on global sales.
Subscribe to PharmaTutor News Alerts by Email >>
